Articles tagged with Cancer Patients
Supportive care, including pain relief and medication to prevent side effects, remains insufficient for many cancer patients, especially those on government-funded schemes in India. This can lead to delayed treatment cycles and poor quality of life. Researchers emphasize the need for better policies and access to effective treatments.
Researchers discovered two genetic mutations in the CCND1 and CCND2 genes in a subset of acute myeloid leukemia patients. These mutations were found in 15% of patients with t(8;21) AML, making them a potential target for new therapies.
A personalized cancer vaccine significantly improved outcomes for patients with acute myeloid leukemia (AML) in a clinical trial, showing protection from relapse in most patients and minimal side effects. The vaccine stimulated powerful immune responses against AML cells, using the body's own defense systems to fight cancer.
A new blood test can detect Merkel cell carcinoma (MCC) earlier and more effectively than traditional imaging studies. The test uses an immune system marker to identify patients at high risk of recurrence, allowing for earlier treatment with immune therapy.
A study led by Dr. Steven A. Rosenberg identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene, leading to cancer regression in a patient with colorectal cancer. The treatment involved infusing tumor-infiltrating lymphocytes into the patient, which recognized and attacked the mutated cells.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
The phase 2 portion of the ZUMA-1 study using KTE-C19 CAR-T therapy achieved complete remission in all 6 patients with refractory primary mediastinal B-cell lymphoma or transformed follicular lymphoma, with manageable toxicities. The treatment was well-tolerated, with grade 3 adverse events occurring in 17% of patients.
A new study found that psychosocial risk factors, such as depression and anxiety, are associated with higher readmission rates and longer hospital stays among blood cancer patients. The study suggests that upfront assessment of patients' ability to cope and social support can improve recovery post treatment.
Researchers found that children with Down syndrome did not experience higher rates of relapse or treatment-related mortality compared to other children treated on the same protocols. However, they suffered more treatment-related mucositis and infections. The study suggests that supportive care can help mitigate these complications.
A study of over 290,000 adults found that even low-intensity smokers had a significantly higher risk of earlier death than never smokers. The risk was particularly strong for lung cancer mortality, with low-intensity smokers experiencing nearly 9 times the risk of dying from lung cancer.
A study from Dana-Farber Cancer Institute found that 30% of lymphoma patients with autologous transplants carry genetic mutations increasing their risk of developing second blood cancers and dying from other causes. The most commonly mutated gene was PPM1D, associated with an abnormal condition called CHIP.
A study by The University of Texas MD Anderson Cancer Center found pre-leukemic mutations can predict the development of therapy-related myeloid neoplasms (t-MNs), a leukemia with poor prognosis. Patients with these mutations are at higher risk, and detecting them earlier could help prevent or treat t-MNs.
The phase 3 ECOG-ACRIN E2905 Intergroup Study found that lenalidomide plus epoetin alpha resulted in improved major erythroid response rates and a similar toxicity profile compared to lenalidomide alone. This combination therapy showed significant benefits for patients with lower-risk, erythropoietin-refractory MDS.
Patients with a history of cancer who experience severe heart attacks have a three times higher risk of noncardiac death but not higher cardiac death rates. They also face increased risks of cardiogenic shock and need more intensive treatment.
A 69-year-old Vietnam war veteran was diagnosed with pleomorphic liposarcoma, a rare type of cancer, after exposure to Agent Orange during his service. The patient's cancer has a high rate of local recurrence and ability to spread to other parts of the body, making early detection crucial.
A team of researchers has established a molecular link between Fanconi anemia and the PTEN gene, strongly associated with uterine, prostate, and brain cancer. The discovery improves understanding of Fanconi anemia and could lead to improved treatment outcomes for some cancer patients.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that alcohol intake is associated with a higher risk of invasive melanoma, especially among individuals who consume more than 20 grams of alcohol per day. White wine was the most clearly associated with increased risk.
A phase I trial of LY3039478 showed the drug's ability to inhibit Notch signalling pathway in patients with various advanced cancers. The treatment resulted in tumour shrinkage and disease stabilisation, particularly in rare cancers like adenoid cystic carcinoma.
A four-week prehabilitation program has shown promising results in preparing cancer patients for surgery by improving their physical fitness and reducing recovery time. The study involved 116 colorectal cancer patients who underwent the program before undergoing surgery.
A clinical trial led by NYU Langone Health found that psilocybin significantly reduces mental anguish in distressed cancer patients for months. The study showed that one-time treatment with psilocybin quickly brought relief from distress that then lasted for over six months in 80% of the participants.
Researchers at MUSC found that inhibiting prostaglandin production with indomethacin increases immune cells and reduces tumor burden in premalignant lesions. This activation of the immune system reduces the progression of lesions to HNSCC.
Ground-breaking studies demonstrate early benefit of targeted treatments in advanced cancers, with dramatic responses seen in patients who have failed standard therapies. Liquid biopsies enable real-time monitoring of patient progress and treatment efficacy.
Cancer Research UK is investing £226 million in cancer research over five years, focusing on translational research and supporting clinical trials. The investment aims to bring better treatments faster to cancer patients, with a particular focus on hard-to-treat cancers.
Researchers at Courage Kenny Rehabilitation Institute present studies on improving walking speed in stroke patients and managing cancer-related cognitive dysfunction, also known as chemobrain. Occupational therapy was found to improve everyday functioning and manage issues like mood, stress, and fatigue in cancer survivors.
In a phase I clinical trial, combination therapy of CB-839 and everolimus resulted in tumor control in 93% of patients with clear cell and papillary renal cell cancer. The median time without cancer growth was 8.5 months, suggesting potential as a treatment option for advanced kidney cancer.
A new study reveals that cancer patients find emotional support in personal stories from peers on online forums, not television entertainment. The researchers found that women make more use of these resources than men, providing a safe space for comfort and community.
Researchers at the University of Kent have developed a new method to extend the life of silicone voice prostheses for throat cancer patients by treating a common fungal infection. By addressing Candida albicans, patients can now carry on using their voice prosthesis for longer, reducing the risk of secondary chest infections.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified the functional role of two distinct DNA modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5-hmC), in glioblastoma tissues. The study found that 5hmC signatures had a strong association with patient survival.
A study of Medicare beneficiaries with cancer found those without supplemental insurance faced the highest out-of-pocket costs. Hospitalizations were a primary reason for these costs, with some patients facing expenses exceeding 63% of their household income.
The grant will help TGen accelerate the computer processing of transcriptomes from thousands of cells using a complex computational algorithm. This process will advance precision medicine by quickly informing doctors with the best options for attacking each individual patient's cancer.
Integrating palliative care into bone marrow transplantation can improve patient quality of life, relieve symptoms, and reduce depression and anxiety. Caregivers also experience benefits, including reduced depression and improved coping skills.
Researchers identified a gene variant that raises risk of severe rheumatoid arthritis, potentially leading to targeted treatment. The study found that the variant correlates with increased MIF production and structural changes in cells, resembling cancerous tissues.
The largest genomic tumor profiling effort showed that large-scale clinical application of the methods is technically feasible, but faces significant challenges and unanswered questions. The study found that at least one actionable mutation was discovered in about two-thirds of patient samples, which could inform treatment decisions.
The University of California, Irvine has received a $1.2 million grant to develop more effective ways for prostate cancer patients and their physicians to customize treatment. The two-year clinical study will use patient-reported disease burden and tumor biomarkers to evaluate the effectiveness of treatment.
Researchers at the University of Hawaii Cancer Center identified a protein called RSK2 as a driver of tumor cell invasion in glioblastoma. Inhibiting RSK2 stops the invasion and enhances chemotherapy effectiveness, offering new hope for patients with this aggressive brain cancer.
Researchers at the University of Notre Dame have made a groundbreaking discovery that could pave the way for pancreatic cancer treatment. The study reveals that exosomes, tiny vesicles released by supporting cells, can educate cancer cells on how to survive chemotherapy, making the disease resistant to treatment.
Dr. Daniel Von Hoff has been recognized as a 'Giant of Cancer Care' for his pioneering work in gastrointestinal cancer and development of new treatments. He is being honored for his commitment to improving the lives of patients and families affected by cancer.
Researchers at Moffitt Cancer Center have developed a novel approach using mathematical modeling to accurately predict patient responses to cancer drugs in virtual clinical trials. This approach enables the identification of optimal treatment schedules that improve outcomes and reduce toxicities for melanoma patients.
A new 'sponge on a string' pill test has been shown to accurately identify people with Barrett's oesophagus who are at low risk of developing oesophageal cancer. This non-invasive test may replace uncomfortable endoscopies for some patients, allowing them to be monitored instead.
Experts question whether following up low-risk patients with symptoms can improve cancer detection, citing a lack of evidence. Researchers recommend ways to improve safety netting, including doctor-patient communication and system reviews.
A new study raises concerns about the effectiveness of expensive new cancer drugs in improving survival rates, citing limitations in clinical trials and high costs. Experts call for stricter approval criteria and improved patient consent processes to ensure fair and equitable treatment.
Researchers have found a link between cancer cachexia and the failure of cancer immunotherapies in patients. By understanding this mechanism, they hope to develop combination therapies that target metabolic abnormalities or hormonal responses, increasing the effectiveness of immunotherapy for more patients.
Researchers at Queen's University Belfast have identified a way to bypass bowel cancer's defence against the drug cetuximab by blocking the ADAM17 protein. This breakthrough could lead to a new combination therapy that delays or prevents cancer recurrence, improving patient outcomes.
A new study of over 14,000 childhood cancer survivors found that while treatments have extended their lifespan, patients do not report better health status. The study, which looked at three decades of therapy, highlights the need for interventions to improve quality of life and health outcomes for these survivors.
A study of 2386 men with localized prostate cancer found that second opinions did not affect treatment choice or quality of care. Men who sought second opinions due to dissatisfaction with their initial urologist were less likely to receive definitive treatment.
A group of circulating tumour cells has been found to be linked to the spread of prostate cancer. The cells' ability to migrate and invade through the body makes them a promising marker for predicting cancer spread. This discovery could potentially be used to monitor patients and make informed treatment decisions.
A new study aims to save lives by giving doctors a practical tool to diagnose cachexia in cancer patients. Cachexia is characterized by muscle wasting and metabolic changes, affecting patient prognosis and quality of life.
Researchers found a combination of immunotherapy options improves overall survival and lowers the risk of life-threatening events in late-stage melanoma patients. PD-1 inhibitors were associated with the lowest risk of life-threatening events, making them a promising first-line therapy option.
Researchers estimate that implementing pictorial warnings on cigarette packs could prevent 652,800 smoking attributable deaths and 46,600 low-birth weight cases by 2065. The study, published online Nov. 3 in the journal Tobacco Control, suggests a direct association between graphic pictures and increased smoking cessation.
A novel therapeutic target and treatment strategy for acute myeloid leukemia (AML) have been discovered, using a small molecule drug to block fructose utilization. This approach shows dramatic therapeutic benefit for AML treatment, improving patient outcomes.
A recent study published in Cancer Epidemiology, Biomarkers & Prevention found that uninsured women under 65 years of age are more likely to experience delays in receiving follow-up mammograms. These delays can contribute to disparities in breast cancer outcomes, including larger tumor size at diagnosis and reduced survival.
A study published in Gynecologic Oncology found that less than half of cervical cancer patients receive standard-of-care treatment, highlighting the need for improved access. Patients who received brachytherapy had better overall survival rates compared to those receiving only two components of SOC.
A study found that an online neurocognitive learning program reduced cognitive symptoms in cancer patients following chemotherapy. Participants who used the program showed improved cognitive function, reduced anxiety and depression, and better quality of life compared to those receiving standard care.
The article explores the economic aspects of cancer care, highlighting the need to assess the value of healthcare innovation. It discusses the rising costs of new treatments and the potential impact on healthcare budgets. The Special Issue provides a review of health economics in cancer research and care.
A new study examines outcomes in colorectal surgery patients, finding that patient factors such as race, income, and insurance status significantly impact readmission rates. Minority-serving hospitals face disproportionately harsh penalties for these outcomes, which may be unfairly influenced by their high patient populations.
A study found that nearly half of cancer patients expect their tumors to shrink after participating in phase I clinical trials, despite the realistic response rate being much lower. The results highlight the need to improve patient information and consent forms.
A new Penn Medicine study fails to find NLR reliable for predicting cancer progression and treatment response in bladder cancer patients. The researchers analyzed data from a prospective clinical trial, which showed that NLR was not effective as a prognostic or predictive biomarker.
The OncoArray technology uses a novel, inexpensive genotyping microarray to analyze DNA variations associated with cancer. Researchers have identified over 100 new loci contributing to common cancers, including lung, colon, breast, ovarian, and prostate cancers.
A study by UC Davis researchers found that terminally ill cancer patients who undergo surgery experience longer hospital stays, readmissions, and discharge to extended care facilities. The study emphasizes the importance of discussing risks and benefits with patients before proposing surgery.
Researchers found that detecting poorly differentiated basal tumor cells in early-stage cancers and overexpressing cell division cycle 25C can predict an increased risk of death. A test for this protein could help determine whether a patient is likely to benefit from drug treatment.